trending Market Intelligence /marketintelligence/en/news-insights/trending/NXS1hT2VuBAneQCr0-0Mew2 content esgSubNav
In This List

Report: Activist investor pushing for change at Alexion Pharmaceuticals

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Banking Essentials Newsletter: September Edition

Blog

Beyond ESG with Climate Stress Testing: Getting Practical at Banks & Insurers


Report: Activist investor pushing for change at Alexion Pharmaceuticals

Elliott Management Corp., a stakeholder in Alexion Pharmaceuticals Inc., is pushing the company to take measures aimed at raising its stock price, The New York Times reported Dec. 7, citing unnamed sources.

The U.S. hedge fund is urging Alexion to put out a more aggressive financial performance guidance or consider strategic options, including a sale of the company.

According to the publication's sources, Elliott Management could initiate a proxy fight to take board seats if the biopharmaceutical company fails to take action.

Following the report, Alexion's stock was up 8.37% to $115.72 as of 2:22 p.m. ET on Dec. 8.